The multiple 7-day intranasal introduction of PGArg and GPArg peptides at a dose of 1 mg per kg body weight before the injection of the diabetogenic dose of alloxan provided the maintenance of normoglycemia in rats. The similar introduction of PGPArg peptide did not provide any protection against the development of diabetes mellitus. The quantity of pancreatic islets in the animals from this group remained quite comparable to the norm, but the total number of cells per islet was below the norm, as well as in the control group. The GPArg peptide showed the best results as a preventive anti-diabetic agent.